The UK's drug regulator rejected Janssen's esketamine nasal spray. Why did the US FDA approve it?
Peter Simons covers a clinical trial that found lithium ineffective at preventing suicide attempts, an essay by Allen Frances on the overdiagnosis of depression and overprescription of antidepressants, a review of the ineffectiveness and dangers of antidepressants, and an analysis that revealed that esketamine failed five of its six clinical trials.
Richard Sears interviews Marcella Ot’alora, therapist and principal investigator for MAPS MDMA-assisted psychotherapy.
An analysis of FDA adverse event reports related to esketamine shows the potential for negative effects such as suicidal and self-injurious ideation.
An interview with Professor John Read who joins us to discuss the UK licensing of esketamine nasal spray (Spravato) for so-called ‘Treatment Resistant Depression’. John led a group of 12 academics and professionals who wrote to the UK regulator expressing concerns.
The UK’s Medicines & Healthcare Products Regulatory Agency is refusing to respond to the concerns of psychiatrists, parliamentarians, patients and other experts about the impending licensing of the street drug ketamine as a treatment for depression.
A new article documents the “flimsy evidence” behind the recent FDA approval of the party drug esketamine for the treatment of depression.
From The Independent: "Ketamine-based treatments for severe depression could further fuel the addiction epidemic sweeping the US, researchers have warned, after a new study found the...
Researchers report that dangerous side effects are not being adequately reported in the trials of ketamine for depression.
Contrary to widely-held belief, a new rigorous trial finds that ketamine is ineffective for delirium and pain associated with surgery, and the drug carries harmful side effects.
From TIME: The club drug ketamine has been found in some small studies to help treat people categorized as having treatment-resistant depression. However, while ketamine has...
A new study, published this month in the Journal of Affective Disorders, investigated the effectiveness of weekly intravenous ketamine injections as a treatment for...
In 2014, then National Institute of Mental Health (NIMH) director, Thomas Insel, speculated that ketamine “might be the most important breakthrough in antidepressant treatment in decades.” A recent review of the research suggests that while ketamine may produce a rapid short-term improvement in depression, the effect is short-lived and the potential for addiction and dependence warrants considerable caution.